Research programme - plectasin antibacterials - Adenium Biotech

Drug Profile

Research programme - plectasin antibacterials - Adenium Biotech

Alternative Names: AP 114; AP 138

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novozymes A/S
  • Developer Adenium Biotech; Novozymes A/S
  • Class Antibacterials; Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium-difficile-infections; Gram-positive infections

Most Recent Events

  • 02 Feb 2018 Discontinued - Preclinical for Clostridium difficile infections in Denmark (IV) (Adenium Biotech pipeline, February 2018)
  • 02 Feb 2018 Discontinued for Gram-positive infections in Denmark (unspecified route) (Adenium Biotech pipeline, February 2018)
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Clostridium-infections in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top